APTw imaging outperforms relaxation-compensated CEST-MRI at 3T in assessing glioma progression after radiotherapy - a preliminary analysis
Nikolaus von Knebel Doeberitz1, Florian Kroh2, Johannes Breitling2, Srdjan Maksimovic1, Laila Koenig3, Juergen Debus3,4, Peter Bachert2,5, Heinz-Peter Schlemmer1,6, Mark E. Ladd2,5,6, Steffen Goerke2, and Daniel Paech1,7
1Division of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 2Division of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 3Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, 4Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 5Department of Physics and Astronomy, University of Heidelberg, Heidelberg, Germany, 6Faculty of Medicine, University of Heidelberg, Heidelberg, Germany, 7Department of Neuroradiology, Bonn University Hospital, Bonn, Germany
In this interim analysis we compared in patients with gliomas the ability of asymmetry-based amide proton transfer weighted (APTw) imaging with Lorentzian-fit-based relaxation-compensated CEST-MRI (MTRRex) of the APT, rNOE and MT signal to differentiate disease progression from treatment induced changes six weeks after completion of radiotherapy. In progressive gliomas, APTw displayed significantly higher signal intensities in contrast enhancing tissue compared to non-progressive gliomas with an AUC of 0.77 in receiver operator characteristic analyses (p 0.03). MTMTRrex showed a trend towards higher signal intensities in progressive tumors. All CEST metrics displayed significant differences in white and gray brain matter signal intensities.
This abstract and the presentation materials are available to members only;
a login is required.